Keeping the Thymus
An old surgical instinct meets new evidence

The money in longevity is chasing a way to regrow the thymus. The two things that already work are quieter: keeping the organ when we operate, and reading it on the scans we have already taken.

This month brought another wave of it — hundreds of millions of dollars, in a single week, toward scanning and supplementing well people, and a growing share of it aimed at one small organ in the front of the chest. The thymus makes T cells, shrinks to fat after puberty, and was written off for most of a century as a gland that had done its job by the time you left school. The new claim is that its decline matters for the rest of adult life, and that regrowing it might slow ageing. That work is real. It is also years away, and its own investigators concede they can restore the organ's size without yet restoring its function. Meanwhile, two things that are neither speculative nor expensive are sitting in plain view.

The organ we were trained to keep

For as long as I have operated, thoracic surgeons have argued — mostly without evidence — for leaving the thymus alone. In training the divide was visible in theatre: those of us on the thoracic side lifted the gland gently off the pericardium and preserved it, while colleagues who needed the space, and the supervisors watching them, were more relaxed about taking it. The larger the thymus, the more it sat in the way, and so the more readily it was sacrificed for exposure. The instinct to keep it was a matter of temperament and training lineage, not something any of us could point to a paper to defend. That is the part that has now changed.

The evidence catches up to the instinct

In 2023 a study from Massachusetts General Hospital compared adults who had the thymus removed during cardiothoracic surgery with matched patients who had similar operations without losing it. Five years on, the thymectomy group had roughly three times the all-cause mortality and twice the cancer incidence, alongside measurably lower production of new T cells and a more inflammatory profile in the blood. Read narrowly, it is the first hard warning that the adult thymus is not disposable.

It should be read carefully, not triumphantly. It is a single centre, it is retrospective, and the obvious confounder runs the other way — a body that is already ageing or unwell may both shrink its thymus and fare worse, without one causing the other. The thoracic community has said as much in print, and a surgeon whose own group works on thymic malignancy has noted that removing all or part of the gland made little difference to recurrence in the patients he studied. The signal is consistent and biologically plausible. It is not yet cause and effect. But it is enough to make the old instinct defensible, and enough that a patient who reads it will not want the organ taken without a reason.

The thymus on a scan you already have

The more interesting development is not about removing the organ at all. This year, in Nature, a group measured thymic health directly from ordinary chest CT — the same scans acquired for lung screening — and found, across the National Lung Screening Trial and the Framingham cohort, that a healthier thymus tracked with lower overall mortality, lower cardiovascular death, and less lung cancer over twelve years of follow-up. A companion paper in Nature went further into my own field: the same measure, read off routine imaging, was associated with how well patients with cancer responded to immunotherapy, with a clear signal in non-small-cell lung cancer.

That last point lands close to daily practice. Immunotherapy is no longer a late option in lung cancer; it has moved to the centre of curative treatment. Adding it to chemotherapy before and after surgery — the neoadjuvant and perioperative strategies established by trials such as CheckMate 816 and IMpower010, and now recommended by NICE — is routine care for locally advanced disease. When the treatment depends on unleashing a patient's own T cells, a measure of the organ that makes those T cells, taken from a scan we already hold, is not a curiosity. It is a plausible read on the host we are asking to do the work.

Where the smart money is

There is a pattern here I recognise from the rest of medicine. The attention and the funding go to the frontier — the injectable that turns back an epigenetic clock, the company promising to regrow tissue — while the usable value sits in the ordinary and the already-paid-for. Preserving an organ we are in the habit of discarding costs nothing. Reading a signal that is already on the scan costs nothing. Neither will make anyone a fortune, which is precisely why neither gets the press release.

The regrowth work may come good, and I hope it does. But the honest position today is that we can restore the thymus's size in a handful of volunteers and cannot yet show we have restored what it does. That is a research programme, not a treatment. What is available now is more modest and more certain: think twice before removing the gland, and pay attention to what it looks like on imaging we are taking anyway.

None of this changes an operation I perform tomorrow. It changes something smaller and more durable — the disposition to keep what can be kept, and to read what is already in front of me. For the patient whose lung cancer surgery now sits inside a course of immunotherapy, that disposition may matter more than the next frontier. The instinct was right. The evidence is beginning to say so.

Related: A nodule is not a diagnosis · Locally advanced lung cancer

← Back to the Journal